Sanofi SA has branched out into RNA therapeutics with an equity investment in Italy-based Resalis Therapeutics which has an antisense oligonucleotide drug in development as a potential treatment for obesity. Announced on 28 October, the size of the investment wasn’t disclosed. Resalis will use the funds to accelerate development of its product, RES-010, through a Phase 2 proof-of-concept trial. The drug targets miR-22, a non-coding RNA that is understood to play a pivotal role in the molecular pathways underlying obesity.
